Aspirin/lisinopril/lovastatin
Alternative Names: CardiaPill; CP-101; polypill-CardioPharmaLatest Information Update: 21 May 2024
At a glance
- Originator CardioPharma
- Class Carboxylic acids; Esters; Lactones; Salicylic acids; Small molecules
- Mechanism of Action ACE inhibitors; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 modulators; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 14 May 2024 CardioPharma files for patent protection for Aspirin/lisinopril/lovastatin in Canada, New Zealand, and Israel, prior to May 2024
- 14 May 2024 CardioPharma has patent protection for Aspirin/lisinopril/lovastatin in Australia, Armenia, Belarus, and the Russian Federation, prior to May 2024
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cardiovascular-disorders in USA (PO, Capsule)